Growth Hormone-Induced Increases in Skeletal Muscle Mass Alleviates the Associated Insulin Resistance in Short Children Born Small for Gestational Age, but Not with Growth Hormone Deficiency

2009 ◽  
Vol 72 (1) ◽  
pp. 38-45 ◽  
Author(s):  
David D. Martin ◽  
Roland Schweizer ◽  
Eckhard Schönau ◽  
Gerhard Binder ◽  
Michael B. Ranke
Keyword(s):  
Insulin Resistance ◽  
Skeletal Muscle ◽  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Muscle Mass ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Skeletal Muscle Mass ◽  
Hormone Deficiency ◽  
Short Children

scholarly journals Evaluation of Clinical Features and Growth Hormone Deficiency in Short Children Born Small For Gestational Age

2018 ◽  
Vol 40 (3) ◽  
pp. 253-257
Author(s):  
Tomomi IKEGAMI ◽  
Shunsuke ARAKI ◽  
Mami KUWAMURA ◽  
Aoi TAKU ◽  
Reiko SAITO ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Clinical Features ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Hormone Deficiency ◽  
Short Children

Decrease of small dense LDL and lipoprotein-associated phospholipase A2 due to human growth hormone treatment in short children with growth hormone deficiency and small for gestational age status

2016 ◽  
Vol 29 (2) ◽  
Author(s):  
Andreas Krebs ◽  
Thomas Kratzin ◽  
Jürgen Doerfer ◽  
Karl Winkler ◽  
Michael Wurm ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Ldl Cholesterol ◽  
Density Lipoprotein ◽  
Human Growth ◽  
Hormone Deficiency ◽  
Cardiovascular Risks ◽  
Small Dense Ldl

AbstractGrowth hormone deficiency (GHD) and small for gestational age (SGA) status are associated with cardiovascular risks. We therefore, investigated antiatherogenic effects of growth hormone (GH).Subfractions of low-density lipoprotein (LDL) and high-density lipoprotein (HDL), lipoprotein-associated phospholipase AThe overall group showed post-treatment reductions of LDL cholesterol (LDL-C) (p=0.016), small-dense LDL cholesterol (sdLDL-C, p<0.001), Lp-PLA2 (p<0.001), and hsCRP (p=0.005), but increase of HDL2a cholesterol (HDL2a-C, p=0.025). SGA children revealed significant correlations between Lp-PLA2 and LDL-C and sdLDL-C both before and after GH, significant reductions of sdLDL-C, Lp-PLA2, hsCRP, and an increase of HDL2a-C. GHD children showed the same lipid responses, though not significantly.Children with GHD or born SGA may benefit from GH by growth acceleration and reduction of cardiovascular long-term risks.

scholarly journals Practical tools to identify short children born small-for-gestational-age eligible for rhGH treatment according to Italian regulation

2019 ◽  
Vol 45 (1) ◽  
Author(s):  
Gianluca Tornese ◽  
Flavia Pricci ◽  
Maria Chiara Pellegrin ◽  
Marika Villa ◽  
Daniela Rotondi ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
National Registry ◽  
Hormone Deficiency ◽  
Number Of Children ◽  
Short Children ◽  
Rhgh Treatment

Abstract Recombinant human growth hormone (rhGH) is an approved and effective treatment for short children born small for gestational age (SGA). Prevalence of children eligible for treatment as SGA is reported to be 1:1800. The latest data from the National Registry of Growth Hormone therapy (RNAOC) showed that the number of children treated with SGA indication is still small (prevalence 0.37/100,000) and these children are significantly less reported than those treated for growth hormone deficiency (GHD), although GHD prevalence is 1:4000–1:10,000. This means that many short children born SGA are still not properly identified, and therefore not treated with rhGH, or misdiagnosed as GHD. This article provides some practical tools for the identification of children eligible for rhGH treatment.

Sign in / Sign up

Export Citation Format

Share Document